MRI Assessment of Placental Health
Boston Children's Hospital · with Massachusetts General Hospital, Massachusetts Institute of Technology · NCT02297724
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · Women only
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- April 2014
- Record last updated
- December 12, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The ultimate goal of this project is to develop methods that allow informed decision-making on the delivery time of fetuses that are at increased risk of stillbirth due to IUGR. In placenta related IUGR pregnancies, there can be multiple concurrent placental pathologies. Although there is no specific correspondence between a single type of pathology and IUGR, the common result of these pathologies is placental insufficiency, which limits the maternal-fetal exchange. Oxygen and nutrition transport is known to be hindered in IUGR placentas due to obstructed or abrupt vasculature, massive fibrin deposition, and inflammation in the villous and intervillous space (villitis). Thus one potential approach to distinguish IUGR pregnancies from normal ones is to assess the efficiency of placental transport. Based on the hypothesis that efficiency of oxygen transport is representative for overall oxygen and nutrition transport in placenta, the investigators propose to characterize the blood oxygenation and blood perfusion in placenta in vivo via MRI, and use it as an index for better stratification in the IUGR risk group. The investigators will also consider alternative MRI approaches such as structural, diffusion and spectroscopy measurements inside the placenta, which might reflect the state of placental transport and reveal the status of placental health.
Specific aims: 1) To correlate the MRI metrics that differentiate placental insufficiency from normal placenta transport with histopathology data of the placenta. 2) To correlate the MRI metrics that reflects placental insufficiency with fetal outcome
Being studied: Oxygen
Conditions: Intrauterine Growth Restriction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- The pregnant mother with twin gestation with diagnosis of selective IUGR based upon obstetrical US findings as following:
- Proven monochorionicity / dichorionicity
- Discordance in estimated fetal weight (EFW). Growth restriction (\<10 percentile of norm) in one or both fetus(es) AND/OR growth discordance (> or = 20%) between twin fetuses.
- The pregnant mother with singleton gestation with diagnosis of IUGR based upon obstetrical US findings as following:
- Proven singleton gestation
- Growth restriction of fetus (\<10 percentile of norm)
- Doppler measurements that indicates placental insufficiency: umbilical artery, middle cerebral artery, uterine artery; or oligohydramnios.
- Gestational age: Bigger than 18 weeks.
- Pregnant mother is between age 18 to 45, clinically stable and can safely tolerate fetal MRI study.
Exclusion Criteria
Fetuses/infants with the following features will be excluded.
- Fetus/infant with chromosomal anomalies or known genetic disorders.
- Fetus/infant with other major congenital malformation.
- Presence of any condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient, quality or completeness of the data.
Pregnant mothers with the following features will be excluded.
- Mothers with contraindication to MRI (with pacemaker, metal in body, oversize).
- Mothers with claustrophobia
- Mothers medically unstable for the MRI study
Recruiting US locations
Boston Children's Hospital
Boston, MA 02115
Site contact: Patricia E Grant, MD · 857-218-5111 · ellen.grant@childrens.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+